Review anchor
Polyunsaturated fatty acid lipoxygenase ALOX12
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Polyunsaturated fatty acid lipoxygenase ALOX12
CHEMBL3687
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Polyunsaturated fatty acid lipoxygenase ALOX12 as ChEMBL target CHEMBL3687, mapped to UniProt P18054. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3687
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18054
Polyunsaturated fatty acid lipoxygenase ALOX12
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Polyunsaturated fatty acid lipoxygenase ALOX12 matters
Polyunsaturated fatty acid lipoxygenase ALOX12 is reviewed as Polyunsaturated fatty acid lipoxygenase ALOX12 (UniProt P18054); Polyunsaturated fatty acid lipoxygenase ALOX12 shows approved-linked disease relevance led by rheumatic disease.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 3002 compounds, and 106 assays, with lead potency reaching pChEMBL 7.3.
Protein context
Polyunsaturated fatty acid lipoxygenase ALOX12
Polyunsaturated fatty acid lipoxygenase ALOX12 Sequence length is 663 aa.
Review this target as Polyunsaturated fatty acid lipoxygenase ALOX12, mapped to UniProt P18054. Sequence length is 663 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P18054
Protein
Disease context
rheumatic disease
Polyunsaturated fatty acid lipoxygenase ALOX12 shows approved-linked disease relevance led by rheumatic disease. 1 linked drug keep the rationale reviewable. Linked drugs include BENOXAPROFEN.
Start review with rheumatic disease because it currently carries approved-linked support. Linked drugs include BENOXAPROFEN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 3002 compounds, and 106 assays for this target. The dominant activity type is IC50. CHEMBL4869861 is the current potency anchor at pChEMBL 7.3.
Use CHEMBL4869861 as the tractability anchor when discussing potency (pChEMBL 7.3).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 7.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Polyunsaturated fatty acid lipoxygenase ALOX12 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P18054, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why rheumatic disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3002
Total Compounds
106
Total Assays
2
Approved Drugs
IC50: 385.0, KI: 7.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4869861
|
7.3 | IC50 | — |
|
|
No preferred name
CHEMBL7660
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL52
|
7.0 | IC50 | — |
|
|
No preferred name
CHEMBL222808
|
6.8 | IC50 | — |
|
|
No preferred name
CHEMBL3113197
|
6.8 | IC50 | — |
Source Header